Please wait a minute...
文章检索
预防医学  2023, Vol. 35 Issue (9): 770-773    DOI: 10.19485/j.cnki.issn2096-5087.2023.09.008
  综述 本期目录 | 过刊浏览 | 高级检索 |
慢性肾脏病流行病学研究进展
朱思懿1, 洪航1, 边学燕2 综述, 许国章1 审校
1.宁波大学医学部公共卫生学院,浙江 宁波 315211;
2.宁波大学附属第一医院,浙江 宁波 315010
Research progress on the epidemiology of chronic kidney disease
ZHU Siyi1, HONG Hang1, BIAN Xueyan2, XU Guozhang1
1. School of Public Health, Health Science Center, Ningbo University, Ningbo, Zhejiang 315211, China;
2. The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, China
全文: PDF(816 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 慢性肾脏病(CKD)具有病程长、预后差、并发症多且治疗费用高等特点,已成为重大公共卫生问题。本文检索2002年2月—2023年3月发表的国内外CKD的流行病学研究文献,对CKD的流行特征、危险因素和防控策略进行综述,发现我国成人CKD人数居亚洲首位,女性、老年人群患病率较高,心血管疾病、糖尿病、高血压和新型冠状病毒感染等是CKD的影响因素。应重视三级预防,优化CKD管理模式,为CKD防治提供支持。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
朱思懿
洪航
边学燕
许国章
关键词 慢性肾脏病流行特征影响因素防控    
Abstract:Chronic kidney disease (CKD) is characterized by long course, poor prognosis, multiple complications and high cost of treatment, thus it has become a major public health problem. Based on review of publications pertaining to the epidemiological study of CKD from February 2002 to March 2023, this article summarizes the epidemiological characteristics, risk factors, prevention and control strategies of CKD. It is found that China has the largest number of adult patients with CKD in Asia, and the prevalence of CKD is higher among females and elderly people. The influencing factors for CKD include cardiovascular diseases, diabetes, hypertension and coronavirus disease 2019. Henceforth, it is of vital importance to emphasize three levels of prevention and optimize the CKD management, so as to support for prevention and control of CKD.
Key wordschronic kidney disease    epidemiological characteristics    influencing factor    prevention and control
收稿日期: 2023-05-10      修回日期: 2023-08-17      出版日期: 2023-09-10
中图分类号:  R181.3  
基金资助:浙江省医学重点学科“现场流行病学”(07-013); 宁波市市级医疗卫生品牌学科(PPXK2018-10); 宁波市“科技创新2025”重大专项(2021Z021)
通信作者: 许国章,E-mail:xuguozhang@nbu.edu.cn   
作者简介: 朱思懿,硕士研究生在读
引用本文:   
朱思懿, 洪航, 边学燕, 许国章. 慢性肾脏病流行病学研究进展[J]. 预防医学, 2023, 35(9): 770-773.
ZHU Siyi, HONG Hang, BIAN Xueyan, XU Guozhang. Research progress on the epidemiology of chronic kidney disease. Preventive Medicine, 2023, 35(9): 770-773.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2023.09.008      或      http://www.zjyfyxzz.com/CN/Y2023/V35/I9/770
[1] 上海慢性肾脏病早发现及规范化诊治与示范项目专家组.慢性肾脏病筛查诊断及防治指南[J].中国实用内科杂志,2017,37(1):28-34.
[2] BIKBOV B,PURCELL C,LEVEY A S,et al.Global,regional,and national burden of chronic kidney disease,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J].Lancet,2020,395(10225):709-733.
[3] MILLS K T,XU Y,ZHANG W,et al.A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010[J].Kidney Int,2015,88(5):950-957.
[4] LIYANAGE T,TOYAMA T,HOCKHAM C,et al.Prevalence of chronic kidney disease in Asia:a systematic review and analysis[J/OL].BMJ Glob Health,2022,7(1)[2023-08-17].https://doi.org/10.1136/bmjgh-2021-007525.
[5] HOCKHAM C,BAO L,TIKU A,et al.Sex differences in chronic kidney disease prevalence in Asia:a systematic review and meta-analysis[J].Clin Kidney J,2022,15(6):1144-1151.
[6] ZHANG L X,ZHAO M H,ZUO L.China Kidney Disease Network(CK-NET)2016 annual data report[J/OL].Kidney Int Suppl,2020,10(2)[2023-08-17].https://doi.org/10.1016/j.kisu.2020.09.001.
[7] 王善志,朱永俊,唐文庄,等.中国成人及老年人群慢性肾脏病患病率Meta分析[J].中国老年学杂志,2017,37(21): 5384-5388.
[8] United States Renal Data System.2022 USRDS annual data report:epidemiology of kidney disease in the United States[DB/OL].[2023-08-17].https://usrds-adr.niddk.nih.gov/2022/suggested-citation.
[9] HARHAY M N,HARHAY M O,COTO YGLESIAS F,et al.Altitude and regional gradients in chronic kidney disease prevalence in Costa Rica:data from the Costa Rican Longevity and Healthy Aging Study[J].Trop Med Int Health,2016,21(1):41-51.
[10] The UK Kidney Association.UK renal registry 24th annual report - data to 31/12/2020[DB/OL].[2023-08-17].https://ukkidney.org/audit-research/annual-report.
[11] ALICIC R Z,ROONEY M T,TUTTLE K R.Diabetic kidney disease challenges,progress,and possibilities[J].Clin J Am Soc Nephrol,2017,12(12):2032-2045.
[12] HUANG Y M,XU D M,LONG J Y,et al.Spectrum of chronic kidney disease in China:a national study based on hospitalized patients from 2010 to 2015[J].Nephrology,2019,24(7):725-736.
[13] DRAWZ P E,BEDDHU S,KRAMER H J,et al.Blood pressure measurement:a KDOQI perspective[J].Am J Kidney Dis,2020,75(3):426-434.
[14] LEE J Y,PARK J T,JOO Y S,et al.Association of blood pressure with the progression of CKD:findings from KNOW-CKD study[J].Am J Kidney Dis,2021,78(2):236-245.
[15] AGGARWAL R,PETRIE B,BALA W,et al.Mortality outcomes with intensive blood pressure targets in chronic kidney disease patients:a pooled individual patient data analysis from randomized trials[J].Hypertension,2019,73(6):1275-1282.
[16] CHEUNG A K,CHANG T I,CUSHMAN W C,et al.Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease[J].Kidney Int,2021,99(3):559-569.
[17] SCHMIDT LAUBER C,HANZELMANN S,SCHUNK S,et al.Kidney outcome after mild to moderate COVID-19[J/OL].Nephrol Dial Transplant,2023[2023-08-17].https://doi.org/10.1093/ndt/gfad008.
[18] CHUNG E Y M,PALMER S C,NATALE P,et al.Incidence and outcomes of COVID-19 in people with CKD:a systematic review and meta-analysis[J].Am J Kidney Dis,2021,78(6):804-815.
[19] SANDERS J S F,BEMELMAN F J,MESSCHENDORP A L,et al.The RECOVAC Immune-response Study:the immunogenicity,tolerability,and safety of COVID-19 vaccination in patients with chronic kidney disease,on dialysis,or living with a kidney transplant[J].Transplantation,2022,106(4):821-834.
[20] LEES J S,ELYAN B M P,HERRMANN S M,et al.The“other”big complication:how chronic kidney disease impacts on cancer risks and outcomes[J].Nephrol Dial Transplant,2023,38(5):1071-1079.
[21] BANSAL N,KATZ R,ROBINSON-COHEN C,et al.Absolute rates of heart failure,coronary heart disease,and stroke in chronic kidney disease an analysis of 3 community-based cohort studies[J].JAMA Cardiol,2017,2(3):314-318.
[22] United States Renal Data System.2020 USRDS annual data report:epidemiology of kidney disease in the United States[DB/OL].[2023-08-17].https://usrds-adr.niddk.nih.gov/2020.
[23] ZHANG L,ZHAO M H,ZUO L,et al.China Kidney Disease Network (CK-NET)2015 annual data report[J/OL].Kidney Int Suppl,2019,9[2023-08-17].https://doi.org/10.1016/j.kisu.2018.11.001.
[24] LIN J J, MOREY F,WU H Y,et al.Prevalence and risk factors for chronic kidney disease in Belize:a population-based survey[J/OL].Lancet Reg Health Am,2021[2023-08-17].https://doi.org/10.1016/j.lana.2021.100013.
[25] 鄢佳妮. 慢性肾脏病5期患者发生主要心血管不良事件的危险因素及预后分析[D].重庆:重庆医科大学,2022.
[26] HSU Y H,CHUANG H C,LEE Y H,et al.Traffic-related particulate matter exposure induces nephrotoxicity in vitro and in vivo[J].Free Radic Biol Med,2019,135:235-244.
[27] WU M Y,LO W C,CHAO C T,et al.Association between air pollutants and development of chronic kidney disease:systematic review and meta-analysis[J/OL].Sci Total Environ,2020,706[2023-08-17].https://doi.org/10.1016/j.scitotenv.2019.135522.
[28] 赵剑刚,郑佳琦.PM2.5暴露与肾脏损害的研究进展[J].预防医学,2021,33(5):473-475.
[29] KUMELA GORO K,DESALEGN WOLIDE A,KERGA DIBABA F,et al.Patient awareness,prevalence,and risk factors of chronic kidney disease among diabetes mellitus and hypertensive patients at Jimma University Medical Center,Ethiopia[J/OL].Biomed Res Int,2019[2023-08-17].https://doi.org/10.1155/2019/2383508.
[30] VALLIANOU N G,MITESH S,GKOGKOU A,et al.Chronic kidney disease and cardiovascular disease:is there any relationship?[J].Curr Cardiol Rev,2019,15(1):55-63.
[31] 徐菱忆,惠淼,朱树宏,等.社区慢性肾脏病的筛查与管理现状[J].北京大学学报(医学版),2022,54(5):1056-1063.
[32] BEETHAM K S,KRISHNASAMY R,STANTON T,et al.Effect of a 3-year lifestyle intervention in patients with chronic kidney disease:a randomized clinical trial[J].J Am Soc Nephrol,2022,33(2):431-441.
[33] 王九生,石锦浩,徐波,等.上海市慢性肾脏病三级防治体系优势及推广意义[J].第二军医大学学报,2018,39(1): 24-28.
[34] SCHRAUBEN S J,APPEL L,RIVERA E,et al.Mobile Health(mHealth)technology:assessment of availability,acceptability,and use in CKD[J].Am J Kidney Dis,2021,77(6):941-950.
[35] LAKSHMANAPRABU S K,MOHANTY S N,RANI S S,et al.Online clinical decision support system using optimal deep neural networks[J/OL].Applied Soft Computing,2019,81[2023-08-17].https://doi.org/10.1016/j.asoc.2019.105487.
[1] 刘晶芝, 胡燕燕, 张学伟, 阿依努尔. 新疆阿勒泰农牧区哈萨克族小学生贫血调查[J]. 预防医学, 2023, 35(9): 807-810.
[2] 刘艳, 沈建勇, 张超, 孙秀秀, 王雨达, 郑佳仪, 张子喆. 2012—2022年湖州市百日咳流行特征分析[J]. 预防医学, 2023, 35(9): 811-813.
[3] 明小力, 杨晓庆, 周瑜, 任天广. 我国夏季型恙虫病流行病学研究进展[J]. 预防医学, 2023, 35(9): 778-780.
[4] 俞素芬, 蒋青林, 戴杰. 2012—2021年吴兴区新报告HIV/AIDS病例晚发现及影响因素分析[J]. 预防医学, 2023, 35(9): 796-799.
[5] 王唐, 董兆鹏, 李淑华, 莫平华, 赵艺明, 宋灿磊. 金山区托幼机构和学校手足口病聚集性疫情分析[J]. 预防医学, 2023, 35(9): 800-802.
[6] 富小飞, 刘砚清, 胡洁, 亓云鹏, 郭飞飞, 查亦薇. 2005—2021年嘉兴市甲型病毒性肝炎和戊型病毒性肝炎流行特征分析[J]. 预防医学, 2023, 35(9): 737-740.
[7] 方柯红, 朱冰, 黄利明, 张旭慧, 刘辉. 杭州市成年居民营养健康知识调查[J]. 预防医学, 2023, 35(8): 710-713.
[8] 王璇, 刘社兰, 曹艳丽, 孙琬琬, 丰燕, 凌锋. 2013—2022年浙江省流行性感冒暴发疫情流行特征[J]. 预防医学, 2023, 35(8): 645-648.
[9] 刘溦, 宋杰, 陈伟伟, 叶丁, 毛盈颖. 硒水平与慢性肾脏病关联的Meta分析[J]. 预防医学, 2023, 35(8): 669-676.
[10] 周星缘, 洪航, 方挺, 许国章. 肺炎流行病学研究进展[J]. 预防医学, 2023, 35(8): 682-686.
[11] 柏旭, 苏洁, 李凤, 徐倩, 沈源, 肖凌凤. 我国成人糖尿病视网膜病变影响因素的Meta分析[J]. 预防医学, 2023, 35(7): 595-601.
[12] 王梦琴, 柴荟琳, 郭宇燕, 任敬娟, 梁瑞峰. 山西省农村居民高血压防治知识、态度、行为调查[J]. 预防医学, 2023, 35(7): 563-569.
[13] 杨冰声, 曹承建. 杭州市美沙酮维持治疗患者脱失的影响因素分析[J]. 预防医学, 2023, 35(6): 522-525.
[14] 姜海波, 洪航, 周健, 李继革, 史宏博, 谭诗文, 褚堃, 张丹丹. 宁波市HIV/AIDS病例新型毒品使用情况调查[J]. 预防医学, 2023, 35(6): 470-474.
[15] 邢超, 王琦梅, 任蒋磊, 陈吉铭, 何琴芬, 蒋卓婧. 2012—2022年绍兴市食源性疾病暴发事件流行特征分析[J]. 预防医学, 2023, 35(6): 506-508,513.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed